Help
RSS
API
Feed
Maltego
Contact
Domain > nippharma.jp
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2016-01-18
114.179.231.91
(
ClassC
)
2025-10-07
153.122.205.16
(
ClassC
)
Port 80
HTTP/1.1 301 Moved PermanentlyDate: Tue, 07 Oct 2025 23:52:23 GMTServer: ApacheLocation: https://nippharma.jp/Content-Length: 229Content-Type: text/html; charsetiso-8859-1 !DOCTYPE HTML PUBLIC -//IETF//DTD HTML 2.0//EN>html>head>title>301 Moved Permanently/title>/head>body>h1>Moved Permanently/h1>p>The document has moved a hrefhttps://nippharma.jp/>here/a>./p>/body>/html>
Port 443
HTTP/1.1 200 OKDate: Tue, 07 Oct 2025 23:52:23 GMTServer: ApacheLast-Modified: Mon, 24 May 2021 10:28:53 GMTETag: 133f-5c310e050fd3aAccept-Ranges: bytesContent-Length: 4927Vary: Accept-EncodingContent-Type: text/html !DOCTYPE HTML PUBLIC -//W3C//DTD HTML 4.01 Transitional//ENhttp://www.w3.org/TR/html4/loose.dtd>html>head>!-- Global site tag (gtag.js) - Google Analytics -->script async srchttps://www.googletagmanager.com/gtag/js?idG-SN16N7SXKE>/script>script> window.dataLayer window.dataLayer || ; function gtag(){dataLayer.push(arguments);} gtag(js, new Date()); gtag(config, G-SN16N7SXKE);/script>title>NiPPharma | human health by development of new combinations/title>meta namedescription contentNiPPharmas goal is to contribute to human health by development of new combinations ofapprovedactive ingredients>meta namekeywords contentニップファーマ,nippharma,にっぷふぁーま,nipファーマ,NiPPharma,NipPharma,ＮＩＰファーマ />meta namegoogle-site-verification contentyMTsG7ZKGoV2u8g7x0VjpedGF-RWp2VAoEndKo-jphM />link relprev hrefhttp://www.nippharma.jp/> link relnext hrefhttp://www.nippharma.jp/corporateprofile/index.html>meta http-equivContent-Type contenttext/html; charsetutf-8>meta http-equivContent-Style-Type contenttext/css>link relstylesheet hrefcss/common.css typetext/css>link relstylesheet hrefcss/top.css typetext/css>meta http-equivContent-Script-Type contenttext/javascript>script typetext/javascript srcjs/smoothscroll.js>/script>/head>body>div classheader>a nametop>/a>div classhead-inner>a href./>div classlogo titleNiPPharma>/div>/a>div classline>/div>h1>contributing to better health/h1>/div>/div>div classmenu>div classmenu-inner>ul classnavigation> li>a href./ titlehome classhome>Home/a>/li> li>a hrefcorporateprofile/ titleCorporate Profile classcprofile>Corporate Profile/a>/li> li>a hrefnewstopics/ titleNews & Topics classnewstopics>News & Topics/a>/li> li>a hrefcorporatepolicy/ titleCorporate Policy classcpolicy>Corporate Policy/a>/li> li>a hrefourtechnology/ titleOur Technology classotechnology>Our Technology/a>/li> li>a hreftechnologyintellectual/ titleTechnology & Intellectual property classtip>Technology & Intellectual property/a>/li>/ul>/div>/div>div idwrapper>div classmain_contents>div classmain_image>h2>NiPPharmas goal is to contribute to human health by development of new combinations ofapproved active ingredients.div classj_link>a hrefhttps://www.nippharma.co.jp/research_development/>img src./img/Japanese_link.png alt日本語サイトへのリンク width25% height25%>/a>/div>/h2>div classnews_topics>p classnt_tit>Establishment of NiPPharma/p>p classsentence>On Nomember 13, 2012, NiPPharma was established with the CliniPro as its parent organization.We hope that our selection and concentration on business brought by this organization will improve the competitiveness of our products.We appreciate your continuing support for the guidance and counseling than ever before./p>p classsentence>Shin-ichi Ono, NiPParma CEO/p>div classmore>a hrefnewstopics/>to Nnews & Topics/a>/div>/div>/div>/div>/div>div idwrapper2>div classmain_contents>div classinfo_box>div classcorp-policy>p>NiPPharma has addressed dry powder inhaler (DPI) .We have established advanced blending techniques which are suitable to DPI production./p>div classmore>a hrefcorporatepolicy/>to Corporate Policy/a>/div>/div>div classour-tec>p>NiPPharmas technology covers a device, strip and dry powder for inhalation. We hope that high quality and convenience will be provided for users./p>div classmore>a hrefourtechnology/>to Our Technology/a>/div>/div>div classtec-intell>p>PatentBlendingbr>ul classpatent>li>5087182br>(registered on September 14, 2012)/li>li>Other 5 patents (pending)/li>/ul>/p>div classmore>a hreftechnologyintellectual/>to Technology & Intellectual property/a>/div>/div>/div>/div>/div>div classfooter>div classfoot-inner>div classnav>ul> li>a href./>Home/a>/li> li>a hrefcorporateprofile/>Corporate profile/a>/li> li>a hrefnewstopics/>News & Topics/a>/li> li>a hrefcorporatepolicy/>Corporate policy/a>/li> li>a hrefourtechnology/>Our technology/a>/li> li classend>a hreftechnologyintellectual/>Technology & Intellectual property/a>/li>/ul>/div>div classcorp-name>p>NiPPharma Co., Ltd./p>p>tel：+81-3-3243-0139 E-mail：info@nippharma.jp/p>/div>div classcopy>p>script languagejavascript srcjs/copyright.js>/script>/p>/div>/div>/div>/body>/html>
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]